A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 84 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-01-16.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 6th largest by enrollment, is one of 4 that started in 2019, is one of 19 in phase 3, and was the 5th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2019.
This study's enrollment of 251 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 18th largest by enrollment of the 116 interventional ones that give a count, is one of 6 that started in 2019, is one of 62 in phase 3, and was the 88th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study evaluated the long-term safety, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Part A: Participants received ELX (elexacaftor) 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for 96 weeks. Part B: Participants from certain countries participated in Part B and continued to receive ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 48 weeks.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed-dose combination (FDC) tablet for oral administration.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Tablet for oral administration.
Also known as: VX-770, ivacaftor
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Baseline up to Week 100
Part A: Absolute Change From Parent Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline at Week 96
Part A: Absolute Change From Parent Study Baseline in Sweat Chloride (SwCl)
Sweat samples were collected using an approved collection device.
Time frame: From Baseline at Week 96
Part A: Absolute Change From Parent Study Baseline in Body Mass Index (BMI)
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).
Time frame: From Baseline at Week 96
Part A: Absolute Change From Parent Study Baseline in BMI Z-score
BMI was defined as weight in kilogram (kg) divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
Time frame: From Baseline at Week 96
Part A: Absolute Change From Parent Study Baseline in Body Weight
Time frame: From Baseline at Week 96
Part A: Absolute Change From Parent Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline at Week 96
The study was conducted as a single part study (Part A) in countries including United States (US), and the protocol for other countries was amended as a regional protocol so that participants in these countries had the opportunity to participate for up to an additional 48 weeks in Part B.
| Milestone | ELX/TEZ/IVA |
|---|---|
| Started | 251 |
| Completed | 215 |
| Not completed | 36 |
| Withdrew: Adverse event | 14 |
| Withdrew: Withdrawal of consent (not due to ae) | 7 |
| Withdrew: Commercial drug is available for participants | 6 |
| Withdrew: Death | 1 |
| Withdrew: Other non-compliance | 2 |
| Withdrew: Other | 6 |
| Participants | Part A: ELX/TEZ/IVA |
|---|---|
| Participants with TEAEs | 241 |
| Participants with SAEs | 38 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | ELX/TEZ/IVA |
|---|---|
| Control-IVA or TEZ/IVA: Change at Week 96 | 4.1 (2.5 to 5.7) |
| ELX/TEZ/IVA: Change at Week 96 | 3.7 (2.2 to 5.2) |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | ELX/TEZ/IVA |
|---|---|
| Control-IVA or TEZ/IVA: Change at Week 96 | -23.0 (-25.8 to -20.1) |
| ELX/TEZ/IVA: Change at Week 96 | -22.6 (-25.4 to -19.9) |
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).
| kg/m^2 | ELX/TEZ/IVA |
|---|---|
| Control-IVA or TEZ/IVA: Change at Week 96 | 1.15 (0.84 to 1.45) |
| ELX/TEZ/IVA: Change at Week 96 | 0.83 (0.54 to 1.11) |
BMI was defined as weight in kilogram (kg) divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
| z-score | ELX/TEZ/IVA |
|---|---|
| Control-IVA or TEZ/IVA: Change at Week 96 | 0.11 (-0.17 to 0.40) |
| ELX/TEZ/IVA: Change at Week 96 | 0.40 (0.17 to 0.62) |
| Kilogram (Kg) | ELX/TEZ/IVA |
|---|---|
| Control-IVA or TEZ/IVA: Change at Week 96 | 3.6 (2.7 to 4.6) |
| ELX/TEZ/IVA: Change at Week 96 | 2.9 (2.0 to 3.8) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | ELX/TEZ/IVA |
|---|---|
| Control-IVA or TEZ/IVA: Change at Week 96 | 7.2 (4.1 to 10.4) |
| ELX/TEZ/IVA: Change at Week 96 | 8.1 (5.1 to 11.1) |
Collected over Day 1 through Safety follow-up (up to Week 100 for Part A and up to Week 52 for Part B). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: ELX/TEZ/IVA | 1/251 (0.4%) | 38/251 (15.1%) | 223/251 (88.8%) |
| Part B: ELX/TEZ/IVA | 0/84 (0%) | 3/84 (3.6%) | 48/84 (57.1%) |
| Event | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 16/251 | 1/84 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 3/251 | 0/84 |
| NauseaGastrointestinal disorders | 0/251 | 1/84 |
| VomitingGastrointestinal disorders | 0/251 | 1/84 |
| Chest painGeneral disorders | 0/251 | 1/84 |
| DepressionPsychiatric disorders | 0/251 | 1/84 |
| Infective exacerbation of bronchiectasisInfections and infestations | 2/251 | 0/84 |
| NephrolithiasisRenal and urinary disorders | 2/251 | 0/84 |
| Pneumothorax spontaneousRespiratory, thoracic and mediastinal disorders | 2/251 | 0/84 |
| Atrial fibrillationCardiac disorders | 1/251 | 0/84 |
| Event | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| HeadacheNervous system disorders | 71/251 | 4/84 |
| CoughRespiratory, thoracic and mediastinal disorders | 65/251 | 5/84 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 61/251 | 17/84 |
| COVID-19Infections and infestations | 52/251 | 17/84 |
| DiarrhoeaGastrointestinal disorders | 48/251 | 4/84 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 42/251 | 5/84 |
| FatigueGeneral disorders | 40/251 | 0/84 |
| NasopharyngitisInfections and infestations | 40/251 | 7/84 |
| PyrexiaGeneral disorders | 36/251 | 2/84 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 34/251 | 3/84 |
The open label Full Analysis Set (OL-FAS) is defined as all enrolled participants who have received at least 1 dose of study drug in the open-label study.
| Age, Continuous(years) | ELX/TEZ/IVA |
|---|---|
| Mean | 37.9 ± 14.4 |
| Sex: Female, Male(Participants) | ELX/TEZ/IVA |
|---|---|
| Female | 124 |
| Male | 127 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 224 |
| Not collected per local regulations | 18 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| White | 225 |
| Black or African American | 2 |
| Other | 5 |
| Not collected per local regulations | 18 |
| More than one race | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing.
Ran from Dec 2019 to primary completion in Dec 2022, 36 months.
Results were first posted in Jan 2024, 1 year 1 month after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 36 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →